PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	gemcitabine	27-38	keratin 20	Homo sapiens	96-100	
20119714-3	2010	The purpose of this report is to describe the successful treatment of gemcitabine-induced TTP/HUS with rituximab, a CD20 monoclonal antibody that has been used for the treatment of refractory idiopathic TTP/HUS.	gemcitabine	70-81	keratin 20	Homo sapiens	116-120	
30639670-6	2019	Pretreatment of cells with gemcitabine (GEM) or polymer-gemcitabine conjugate (2P-GEM) enhanced CD20 expression levels thus increasing apoptosis induced by DFMT.	gemcitabine	40-43	keratin 20	Homo sapiens	96-100	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	29-33	
30465822-4	2019	The extracellular actuation by surface CD20 crosslinking boosts robust activations of numerous intracellular responses, and promotes cancer cell susceptibility to various anticancer drugs, including docetaxel (microtubule stabilizer), gemcitabine (nucleoside analogue) and GDC-0980 (PI3K/mTOR inhibitor).	gemcitabine	235-246	keratin 20	Homo sapiens	39-43	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	114-118	
29595951-5	2018	Moreover, the restoration of CD20 expression by the pretreatment of cells with a polymer-gemcitabine conjugate, a CD20 expression enhancer, unleashes the full potential of DFMT in the CD20-deficient resistant cells.	gemcitabine	89-100	keratin 20	Homo sapiens	114-118	
29212973-0	2017	[Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].	gemcitabine	176-187	keratin 20	Homo sapiens	12-16	
29561444-0	2018	T-cell lymphoma with abundant CD20 expression showing a good response to rituximab with gemcitabine, oxiplatin, and L-asparaginase (R-pGEMOX): A case report.	gemcitabine	88-99	keratin 20	Homo sapiens	30-34	
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	gemcitabine	130-141	keratin 20	Homo sapiens	30-34	
29212973-11	2017	In this case, we demonstrated CD20-negative conversion following rituximab and CD20-positive reversion after using vorinostat and gemcitabine.	gemcitabine	130-141	keratin 20	Homo sapiens	79-83	
26920337-0	2016	Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.	gemcitabine	0-11	keratin 20	Homo sapiens	96-100